| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.55(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
69,133 |
99,133 |
204,762 |
249,340 |
| Total Sell Value |
$3,373,178 |
$4,809,278 |
$8,488,919 |
$10,478,837 |
| Total People Sold |
8 |
8 |
9 |
12 |
| Total Sell Transactions |
10 |
11 |
21 |
34 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dier Mardi |
CFO & Executive Vice President |
• – – |
2022-03-01 |
4 |
AS |
$66.62 |
$35,575 |
D/D |
(534) |
38,228 |
|
-2% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
227,840 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$158,156 |
D/D |
(2,374) |
213,840 |
|
2% |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
47,938 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$187,935 |
D/D |
(2,821) |
33,938 |
|
2% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,710 |
17,046 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$56,161 |
D/D |
(843) |
13,229 |
|
2% |
|
| Pinion John Richard |
See Remarks |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
59,266 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$299,657 |
D/D |
(4,498) |
45,266 |
|
2% |
|
| Parschauer Karah Herdman |
EVP and Chief Legal Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
39,578 |
|
- |
|
| Parschauer Karah Herdman |
EVP and Chief Legal Officer |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$192,265 |
D/D |
(2,886) |
25,472 |
|
2% |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
36,317 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$180,740 |
D/D |
(2,713) |
22,317 |
|
2% |
|
| Huang Dennis Karl |
See Remarks |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
51,040 |
|
- |
|
| Huang Dennis Karl |
See Remarks |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$215,449 |
D/D |
(3,234) |
36,914 |
|
2% |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2022-01-30 |
4 |
S |
$66.30 |
$109,859 |
D/D |
(1,657) |
36,759 |
|
27% |
|
| Kakkis Emil D |
President & CEO |
• • – |
2021-10-14 |
4 |
D |
$81.00 |
$69,093 |
D/D |
(853) |
594,347 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$29,129 |
D/D |
(359) |
38,416 |
|
17% |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$25,153 |
D/D |
(310) |
28,358 |
|
17% |
|
| Pinion John Richard |
See Remarks |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$29,048 |
D/D |
(358) |
49,764 |
|
17% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$11,360 |
D/D |
(140) |
14,072 |
|
17% |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$24,585 |
D/D |
(303) |
25,030 |
|
17% |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$29,048 |
D/D |
(358) |
40,148 |
|
17% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$23,206 |
D/D |
(286) |
216,266 |
|
17% |
|
| Dier Mardi |
CFO & Executive Vice President |
• – – |
2021-10-14 |
4 |
AS |
$81.16 |
$264,663 |
D/D |
(3,261) |
38,762 |
|
-17% |
|
627 Records found
|
|
Page 5 of 26 |
|
|
0.10 (0.23%) 
